19 Nov03:08 Business Livsayis FDA Approval Hands Regeneron a New Neurology Franchise The Livsayis FDA approval gives Regeneron its first siRNA drug and first neurology medicine, treating generalized myasthenia gravis with four doses a year. Keith Howard · 8 min ago